As investors await the opening of Anthem Biosciences IPO, here are the key strengths and risks outlined in its Red Herring ...

On the financial front, Anthem reported a net profit of ₹451.3 crore for the financial year ended March 2025, up 22.9% from ...

We’re now the second source for many products made in China—and the first choice for new ones,” Ajay Bhardwaj, CEO and Founder of Anthem told Moneycontrol in an interview.

Anthem Biosciences is preparing to launch its Rs 3,395-crore IPO on July 14, entirely an offer-for-sale by selling ...

Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot year ...

Anthem Biosciences files DRHP for Rs. 3,395 crore IPO: Our Bureau, Bengaluru Thursday, January 2, 2025, 10:30 Hrs [IST] Anthem Biosciences Limited, an innovation-driven and technology-focused contract ...

Anthem Biosciences live in four months with unified quality management system BANGALORE, INDIA – Media OutReach Newswire – 21 December 2023 – Veeva Systems (NYSE: VEEV) today announced that ...

Anthem Biosciences Pvt., a Bengaluru-based contract drug researcher and manufacturer, is considering an initial public offering in India that could raise about $400 million, according to people ...

Anthem Biosciences, an India-based CDMO, made a last-minute filing at the end of 2024 to announced its plans for a $397 million (33.95 billion rupee) public offering.

Anthem Biosciences on Tuesday (December 31, 2024) filed preliminary papers with capital markets regulator Sebi to float a ₹3,395-crore initial public offering.

BANGALORE, INDIA - Media OutReach Newswire - 21 December 2023 - Veeva Systems (NYSE: VEEV) today announced that Anthem Biosciences, a rapidly expanding contract research and innovation service ...